225Ac-DOTATOC治疗生长抑素受体阳性实体瘤的剂量与5年血液及肾脏毒性随访
结果显示单次剂量>40 MBq或约每4个月重复给药>20 MBq时出现剂量依赖性急性血液学毒性;约20 MBq/周期(每4个月重复)且累积60-80 MBq一般可避免3/4级急慢性血液学毒性,但慢性肾毒性仍可见,且既往肾脏危险因素是重要协同因素。
要点
- 单次>40 MBq或每4个月重复>20 MBq时出现剂量依赖性急性血液学毒性。
- 约20 MBq/周期(每4个月重复)且累积60-80 MBq一般避免3/4级血液学毒性。
- 慢性肾毒性可见,但既往肾脏危险因素是重要协同因素,年eGFR平均下降8.4 ml/min(9.9%)。
核心结论
- 约20 MBq/周期(每4个月重复)且累积剂量达60-80 MBq一般可避免晚期恶性肿瘤患者的急性和慢性3/4级血液学毒性。
- 在这些剂量下观察到慢性肾毒性,但既往存在的肾脏危险因素是重要协同因素。
研究设计与样本
- 获取基线及随访68Ga-DOTATOC PET/CT、实验室检查和肾闪烁显像,并通过本地癌症中心或与外部肿瘤科医生合作进行长期随访。
主要发现
- 单次剂量>40 MBq或约每4个月重复给药>20 MBq时出现剂量依赖性急性血液学毒性。
- 2例患者在>4年延迟后发生治疗相关肾衰竭,但与给予的放射性活度无关,其他临床危险因素对肾功能下降有重要贡献。
- 患者年eGFR下降未呈现明确剂量效应关系,即使既往接受β治疗的患者也是如此;平均年eGFR损失为8.4 ml/min(9.9%)。
关键数值与推荐
- 单次剂量>40 MBq或约每4个月重复给药>20 MBq时出现剂量依赖性急性血液学毒性。
- 约20 MBq/周期(每4个月重复)且累积剂量达60-80 MBq一般可避免3/4级急慢性血液学毒性。
- 平均年eGFR损失为8.4 ml/min(9.9%)。
临床怎么用
- 对于生长抑素受体阳性晚期恶性肿瘤患者,可考虑约20 MBq/周期(每4个月重复)且累积60-80 MBq的225Ac-DOTATOC方案以降低3/4级血液学毒性风险。
- 治疗期间需长期监测血液学毒性和肾功能,尤其对既往存在肾脏危险因素的患者。
局限性
- 本数据仅为更精确界定225Ac-DOTATOC安全阈值的起点,需进一步研究。
- 慢性肾毒性观察中既往肾脏危险因素是重要协同因素,且肾衰竭与给予的放射性活度无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this retrospective analysis is to estimate the most appropriate single cycle and cumulative doses of 225Ac-DOTATOC in patients treated for somatostatin-receptor-expressing cancers. METHODS: 225Ac-DOTATOC was administered to thirty-nine patients with various somatostatin-receptor-positive tumors. Baseline and follow-up 68Ga-DOTATOC PET/CT, lab tests, and renal scintigraphy were obtained. Patients received long-term follow-up either at the local cancer center or in close collaboration with external oncologists. Acute and chronic hematological toxicity was evaluated quantitatively over time. Long-term follow-up of creatinine was used to approximate the annual loss of estimated GFR (eGFR). RESULTS: Dose-dependent acute hematological toxicity was seen at single doses above 40 MBq or repeated doses greater than approximately 20 MBq 225Ac-DOTATOC at 4 month intervals. Treatment-related kidney failure occurred in 2 patients after a delay of >4 years but was independent of administered radioactivity, and other clinical risk factors were important contributors to renal decline. In general, the annual decline of eGFR among patients did not follow a clear dose-effect relationship even in patients with previous β-therapy. An average eGFR-loss of 8.4ml/min (9.9%) per year was observed which is similar to the experience with β-therapy studies. CONCLUSION: Treatment activities of approx. 20 MBq per cycle (4 monthly repetition) and cumulative doses up to 60-80 MBq generally avoided both acute and chronic grade 3/4 hematotoxicity in patients with advanced stage malignancies. Chronic renal toxicity was observed at these doses, but pre-existing renal risk factors were important co-factors. These data represent a starting point for additional research to more precisely define safety thresholds of 225Ac-DOTATOC.
引用
- Kratochwil C, Apostolidis L, Rathke H, et al. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging. 2021. PMID: 34448031. doi:10.1007/s00259-021-05474-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。